Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous Imatinib (Impentri) for COVID-19 ARDS
NCT04794088Phase 2Terminated
- Start
- Mar 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of olaparib + durvalumab in acute respiratory distress syndrome (ARDS) (2 arms). Primary endpoint: Change in extravascular lung water index at Day 4. Started Mar 2021; status: terminated.
02
Drugs
olaparib + durvalumab
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04794088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04794088.